Our Partners


CHS on facebook and YouTube


Rendez-vous 2015 presented by Biogen

The Canadian Hemophilia Society is pleased to invite you to attend Rendez-vous 2015 which will be held May 28-31, 2015 in Halifax.

This key event will feature the Medical and Scientific Symposium: Living with a Bleeding Disorder: Changing Perspectives, the CHS Annual General Meeting, a youth workshop, a community workshop about the past, present and future and annual meetings of the four health care professional groups.

Rendez-vous is organized jointly by the Canadian Hemophilia Society (CHS), the Association of Hemophilia Clinic Directors of Canada (AHCDC), the Canadian Association of Nurses in Hemophilia Care (CANHC), the Canadian Physiotherapists in Hemophilia Care (CPHC), and the Canadian Social Workers in Hemophilia Care (CSWHC).

Rendez-vous 2015 is presented by Biogen and sponsored by Baxter, Bayer, CSL Behring, Gilead, Novo Nordisk, Octapharma and Pfizer.

This biennial conference will explore state-of-the-art advances in treatment and research benefiting people with inherited bleeding disorders. Among many other stimulating topics presented at the Medical and Scientific Symposium, attendees will hear from experts about pain management, adherence to prophylaxis protocols, anxiety and needle phobia, the latest in HCV treatments, and fitness.

Attending this invaluable meeting is an extraordinary opportunity, in only one weekend, to gain new knowledge at the medical and scientific sessions and community workshops, to network with peers and friends, to visit the pharmaceutical industry exhibits and to take an active part in your organization’s Annual General Meeting.

We hope you can join us!

Rendez-vous 2015 - FINAL PROGRAM

2015 research grants allocated

The Peer Review Committee, under the leadership of Dr. Nancy Dower, completed its grant review process in February 2015. Its recommendations were endorsed by the CHS Board of Directors in March.

Click here to read about the research projects funded for 2015-2016.

Important documents updated

The CHS has recently updated five widely consulted informative documents on three related topics:

  • access to insurance (life, mortgage, travel, health insurance for overseas students, group) for people with bleeding disorders;

  • an overview of the different compensation programs for blood-borne HIV and HCV infection created since 1989.

Please click on the links above to access the revised documents.

Héma-Québec announces winners in FVIII and IX tenders

See all the details in Hemophilia Today – March 2015 – page 3 (revised article as of February 26).

Products in the pipeline - NEW UPDATE (February 23, 2015)

Never have so many clotting factor concentrates been in development or “in the pipeline”. So many, in fact, that it has become difficult to keep track of them all. So the CHS is publishing five charts, one each for factor VIII, factor IX, inhibitor products, other coagulation products, and one for factor VIII and IX and inhibitors together, to help everyone stay informed of their progress through preclinical work, clinical trials and regulatory approval.

Click here for more details.

Hemophilia Today - March 2015

Online consultation about Hemophilia Today

The latest issue of Hemophilia Today is now available online on the CHS Web site (see above).

As you will notice, the magazine is undergoing some changes. You can read about them in the Word from the Editor. We are now calling upon you to guide us in additional changes that could further improve the CHS’ newsmagazine.

In order for you to do so, we have created a short online consultation. Please do not hesitate to share your input. We are very eager to read your opinions and ideas.

Click here to access the confidential survey. THANK YOU!

Congratulations to the Quebec Chapter and its twin, the Nicaraguan Hemophilia Association, for the WFH 2014 Hemophilia Organization Twins of the Year Award

The WFH Hemophilia Organization Twinning Committee met recently to review the reports received from twins around the world. The Quebec Chapter (CHSQ) – Nicaraguan Hemophilia Association twinning stood out from an impressive pool of candidates and the committee agreed to present it with the 2014 Hemophilia Organization Twins of the Year Award.

The committee was impressed by the scope of the activities undertaken in 2014 including the inauguration of the NMO office, organization of three educational workshops for members, training on self-infusion and prevention, initiation of board training and advocacy training and the continued communication between partners.

The World Federation of Hemophilia’s Twinning Program links patient organizations and treatment centres in emerging and established countries through exchanges, trainings, workshops, patient education and other activities to improve treatment and care for people with bleeding disorders.

UPDATED CHS resource about HCV treatment support for 1986-1990 claimants

Accessing treatments for hepatitis C through the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement: What you need to know

If you are a patient who received tainted blood or blood products and a registered claimant of the Hepatitis C (HCV) 1986-1990 Class Actions Settlement, now is a good time to speak to your doctor about new treatments for HCV. Treatment has progressed significantly, and it may be the right time for you to seek a cure.

People who are approved claimants under the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement may be reimbursed for their costs for treatments and generally accepted hepatitis C medications that are not recoverable under any public or private health care plan. Many companies that make and sell hepatitis C medications have programs to support patients throughout treatment.These programs offer assistance by providing drugs upfront to the 86-90 claimants through their specialty pharmacy. Once the 86-90 plan issues the reimbursement cheques to the patients for their treatment, they, in turn, must reimburse the pharmacy directly.

Because this is not well known by the claimants themselves nor their health care providers, the CHS has developed a new resource to provide more information. Note that the resource was recently updated to include new and additional patient support programs.

Please click here for more information and access to the new brochure.

Revised version for one of the most popular documents in the CHS catalogue

2015 version now available.

Please click here to download the document.

Please contact the CHS office if you wish to receive copies of the document:

Desmopressin - A Guide for Patients and their Caregivers

Second editions of three booklets now available

HIRT? - An innovative injury self-management App

Do you have mild hemophilia?

Have you had injuries that seemed minor at first but then turned into a more serious problem?

Not sure what to do when you have a bleed?

Then HIRT? (Hemophilia Injury Recognition Tool) is just what you need!

This new App, developed following research funded by the CHS/Baxter Canada Inherited Bleeding Disorders Fellowship Program for Nurses and Allied Health Care Professionals, was designed with the help and feedback from young men age 18-35 with mild hemophilia.

Click here for all the details.

E-novella spreading the word on bleeding disorders on Wattpad

One in 100 Canadians carries an inherited bleeding disorder gene, yet so many remain undiagnosed. In an effort to educate a younger audience about the symptoms and risks of bleeding disorders, we’ve developed an e-novella – entitled ‘A Negative’ – to spread the word in an engaging and memorable way.

Playing off the popular Harlequin romance genre, ‘A Negative’ tells the story of a young woman unknowingly living with von Willebrand disease. We’ve published the e-novella on Wattpad – the world’s largest online community of writers and readers – in order to connect with young women across Canada. This unique approach introduces the issue into a different medium, enabling us to speak to and educate an engaged but unsuspecting audience.

CLICK HERE for the press release.

CLICK HERE to read 'A Negative'.

CHS support to research and market studies

Several times in the past, the CHS has invited the bleeding disorder community to participate in research and market studies. Once again, we wish to reinforce the importance of these projects and the benefit for our community to participate. Research and market studies are crucial to the advancement of care and treatment. This is your chance to voice your concerns and priorities when it comes time to your care and treatment or those of your child. At many levels, these studies are often one step closer towards a better quality of life.

These studies, however, need our community to gather sufficient data to be relevant.

Please take the time to see what is presently happening with regards to research and market studies and to see if you could take an active part in them.

On-going RESEARCH studies currently recruiting participants:
  • Invitation to families of children with bleeding disorders to participate in an interview-based research study
  • Do you have mild hemophilia?
  • Carriers of hemophilia wanted for survey-based research study
  • Web survey about perceived well-being in people with hemophilia

Click here
for more details on each of these research studies.


On-going MARKET studies currently recruiting participants:
  • Absolutdata is currently looking for adults and youth as well as parents of children with hemophilia A for a market research study.
  • HealthPulse is currently looking for patients with hemophilia A and a low titre inhibitor who are undergoing immune tolerance induction (ITI) therapy or who are currently being treated with a bypassing agent (Niastase, FEIBA).

Click here
for more details on each of these market studies.

A bandage is not enough.


Click here for more information about this important public awareness and outreach campaign or to download promotional material.

You and your family depend on research...

Make a difference - Help save lives

We can stop the suffering of those living with hemophilia and other bleeding disorders. But we can't do it alone. Only with the generous financial support of caring Canadians can we make our dream come true.

To support us